LifeMD (NASDAQ:LFMD) Rating Increased to Outperform at Mizuho

Mizuho upgraded shares of LifeMD (NASDAQ:LFMD) from a neutral rating to an outperform rating in a research note issued to investors on Monday, Marketbeat.com reports. They currently have $8.00 price objective on the stock, up from their previous price objective of $6.00.

Other equities analysts have also recently issued reports about the stock. Loop Capital set a $10.00 target price on shares of LifeMD in a research note on Thursday. Lake Street Capital dropped their price target on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Wall Street Zen upgraded shares of LifeMD from a “sell” rating to a “hold” rating in a research note on Saturday. B. Riley Financial decreased their price objective on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Stock Performance

LFMD opened at $4.40 on Monday. The business’s 50-day simple moving average is $3.34 and its 200 day simple moving average is $4.50. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The firm has a market capitalization of $211.07 million, a PE ratio of 16.92 and a beta of 1.92.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). The company had revenue of $46.87 million during the quarter, compared to the consensus estimate of $48.57 million. LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. On average, research analysts forecast that LifeMD will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LFMD. Vanguard Group Inc. raised its stake in LifeMD by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock valued at $15,120,000 after acquiring an additional 140,749 shares during the period. Federated Hermes Inc. lifted its holdings in LifeMD by 278.1% during the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after purchasing an additional 721,018 shares during the last quarter. Geode Capital Management LLC boosted its position in LifeMD by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 959,700 shares of the company’s stock worth $3,273,000 after purchasing an additional 11,324 shares during the period. Royce & Associates LP boosted its position in LifeMD by 11.7% during the fourth quarter. Royce & Associates LP now owns 909,651 shares of the company’s stock worth $3,102,000 after purchasing an additional 95,200 shares during the period. Finally, Whetstone Capital Advisors LLC increased its holdings in shares of LifeMD by 89.6% in the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock valued at $2,397,000 after purchasing an additional 332,269 shares during the last quarter. 35.52% of the stock is owned by institutional investors and hedge funds.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.